Andy Chen
Stock Analyst at Wolfe Research
(4.34)
# 366
Out of 5,054 analysts
40
Total ratings
52%
Success rate
25.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $19.51 | - | 1 | Nov 6, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Peer Perform | n/a | $54.25 | - | 2 | Oct 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $451.95 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $29.71 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $66.58 | -26.40% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $17.98 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $70.70 | -22.21% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $11.75 | +419.15% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $10.18 | +106.29% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $33.56 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $42.94 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $28.20 | -29.08% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $35.20 | -46.02% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $22.89 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $889.64 | -21.65% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $108.16 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $24.37 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $63.42 | +2.49% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $541.50 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $28.43 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $29.48 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $72.45 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $55.21 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $20.90 | -18.66% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $429.22 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $193.69 | -78.32% | 1 | Feb 15, 2024 |
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.51
Upside: -
Akero Therapeutics
Oct 10, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $54.25
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $451.95
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $29.71
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $66.58
Upside: -26.40%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $17.98
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $70.70
Upside: -22.21%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $11.75
Upside: +419.15%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $10.18
Upside: +106.29%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $33.56
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $42.94
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $28.20
Upside: -29.08%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $35.20
Upside: -46.02%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $22.89
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $889.64
Upside: -21.65%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $108.16
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $24.37
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $63.42
Upside: +2.49%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $541.50
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $28.43
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $29.48
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $72.45
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $55.21
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $20.90
Upside: -18.66%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $429.22
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $193.69
Upside: -78.32%